Get started
Author

Matthew Birrenkott

Observed name: Birrenkott Matthew
OpenAlex ID: A5029910356
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
2023 · Ashish M. Kamat, Yair Lotan, et al. · Journal of Clinical Oncology · 15
PDF
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.
2023 · Ashish M. Kamat, Gary D. Steinberg, et al. · Journal of Clinical Oncology · 8
Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
2022 · Christopher J. Hoimes, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 8
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.
2024 · Michiel Simon Van Der Heijden, Shilpa Gupta, et al. · Journal of Clinical Oncology · 3
RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.
2026 · Mrinal M. Gounder, Piotr Rutkowski, et al. · Journal of Clinical Oncology · 2
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
2026 · Rashmi Chugh, Arun Singh, et al. · Journal of Clinical Oncology
PDF
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.
· van Der Heijden Michiel S., Gupta Shilpa, et al. · Institutional Repositories DataBase (IRDB)
Works count: 7
Citation count: 36
H-index: 3
I10-index: 1
Year
Topic
Type